Get An in-Depth Analysis of Advances in Cancer Therapeutics and Diagnostics.LYON, France -- Reportlinker.com announces that a new market research report related to the world wide pharmaceutical market is now available to its catalogue. Innovations in Cancer: Novel therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , new diagnostics (1) Software routines that test hardware components (memory, keyboard, disks, etc.). Diagnostics are often stored in ROM chips and activated on startup. (2) Error messages in a programmer's source code that refer to statements or syntax that the compiler or assembler and future R&D strategies http://www.reportlinker.com/p045764/ innovation-cancer-therapeutic.html (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller , oncogenomics and new methods in cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. . These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer. Innovations in Cancer provides a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and in-depth analysis of advances in both cancer therapeutics and diagnostics to provide a complete picture of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities highlighting companies with specialised Adj. 1. specialised - developed or designed for a special activity or function; "a specialized tool" specialized specific - (sometimes followed by `to') applying to or characterized by or distinguishing something particular or special or unique; "rules with capabilities in the discovery and the characterization A rather long and fancy word for analyzing a system or process and measuring its "characteristics." For example, a Web characterization would yield the number of current sites on the Web, types of sites, annual growth, etc. of next-generation drug targets. Use this report to understand how the cancer market is developing, identify areas of unmet un·met adj. Not satisfied or fulfilled: unmet demands. medical need and align align (  līn),v to move the teeth into their proper positions to conform to the line of occlusion. your product pipeline to achieve clinical and commercial success. Key findings of the report... * In 2000, cancer was responsible for 12% of the 56m deaths world wide. In the same year, 5.3m men and 4.7m women developed a malignant tumor malignant tumor n. A tumor that invades surrounding tissues, is usually capable of producing metastases, may recur after attempted removal, and is likely to cause death unless adequately treated. . The World Health Organisation predicts a rise in cancer incidence by 50% by the year 2020, largely due to lifestyle factors. * Roche, Sanofi-Aventis and Amgen were the leading players in the cancer market in 2005, generating sales of $8.5bn, $3.9bn and $3.8bn respectively. * Unmet patient need is the major driver of innovation in both cancer therapeutics and diagnostics. There is significant need for high-sensitivity diagnostic methods to detect the presence of early-stage disease. * Small interfering RNAs Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, are a class of 20-25 nucleotide-long double-stranded RNA molecules that play a variety of roles in biology. are emerging as potential innovative cancer therapies. Whilst the delivery of these molecules remains limited, the number of candidates in development is increasing, with over 25 cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine in the pipeline. * Competitive pressures and reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. issues will increase the demand for better evidential ev·i·den·tial adj. Law Of, providing, or constituting evidence: evidential material. ev information on efficacy and the need for a diagnostic component to the clinical decision-making process. Key questions answered in this report * What are the key unmet needs in the cancer market? * How are reimbursement issues affecting innovation in the cancer market? * Who are the leading innovators innovators people who will try new things. early innovators important figures in the farming or client community because they are the leaders in the introduction of new techniques and management systems. in the global cancer market? * Why are theranostic considerations becoming increasingly important in the cancer field? * How will scientific advances drive new opportunities in the cancer market in the next 5 years? * What will be the leading innovative cancer drugs and diagnostics in the next 5 years? * What impact will cancer stems cells, siRNA's and vaccines have on drug development to 2011? Top five reasons to order your copy today * Gain a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and how this will influence the development of future strategies. * Identify the greatest areas of unmet medical need in the cancer field and how this continues to drive innovation, enabling you to anticipate future trends in the market. * Assess your organisation's position in the market-place, identify competitive innovations and understand how companies are developing better drugs and diagnostics which will displace dis·place tr.v. dis·placed, dis·plac·ing, dis·plac·es 1. To move or shift from the usual place or position, especially to force to leave a homeland: today's technologies. * Discover the products that are being developed by the leading companies in the cancer market across the 'top four' cancers including breast, colorectal co·lo·rec·tal adj. Relating to the colon and the rectum, or to the entire large bowel. colorectal pertaining to or of the nature of the colon and the rectum. , lung and prostate prostate /pros·tate/ (pros´tat) a gland surrounding the bladder neck and urethra in the male; it contributes a secretion to the semen.prostat´ic pros·tate n. The prostate gland. adj. . * Understand how the use of oncogenomics will allow for better targeting of cancer, creating opportunities for the development of newer more effective products. Table of Contents Executive Summary Current market landscape and dynamics Drivers and resistors of innovation Innovations in cancer therapeutics Innovations in cancer diagnostics New R&D strategies in cancer The future of the cancer market and conclusions Chapter 1 Current market landscape and dynamics Summary Introduction Cancer epidemiology Sales by drug class Sales by brand Sales by company Sales by country Gold standard treatments Lung cancer Colorectal cancer Breast cancer Ovarian Uterine Leukemia Prostate Pancreatic Lymphomas Unmet need Innovation in the cancer market Targeted therapy Cancer diagnostics Chapter 2 Drivers and resistors of innovation Summary Introduction Drivers of innovation Cancer statistics Need Risk Scientific advances Diagnostics Resistors Market fragmentation Reimbursement Chapter 3 Innovations in cancer therapeutics Summary Introduction Key trends Key innovations Targeted therapies Cancer vaccines Small interfering RNAs Pipeline Addressing unmet need Chapter 4 Innovations in cancer diagnostics Summary Introduction Cancer biomarkers Predicting cancer Diagnostic innovations by indication Lung Colon & rectum Breast Ovary Uterus and cervix Leukemia Prostate Pancreas Lymphomas Chapter 5 New R&D strategies in cancer Summary Introduction Background Oncogenomics Scientific approaches Small interfering RNA Biologicals Gene expression and biomarkers Arrays Drug delivery Cancer stem cells Looking ahead Chapter 6 The future of the cancer market and conclusions Summary Introduction Key trends The future Chapter 7 Appendix Index List of Figures Figure 1.1: Incidence per cancer indication and country, 2005 Figure 2.2: Drivers and resistors of innovation in the cancer market Figure 3.3: Companies developing new therapeutics for the "top four" cancers, 2007 Figure 3.4: Numbers of drugs in development for the "top four" cancers, 2006 Figure 3.5: Top companies developing therapeutics for the "top four" cancers, 2006 Figure 3.6: Phase I-III pipeline for the "top four" cancers, 2006 Figure 4.7: Categorization of cancer diagnostic tests Figure 4.8: Overview of diagnostics for 10 leading cancers, 2006 List of Tables Table 1.1: Incidence of 9 major tumor types in the 7 major markets, 2005 Table 1.2: Global cancer market sales by drug class, 2004-05 Table 1.3: Top 20 global cancer brands, 2004-05 Table 1.4: Top 20 cancer companies by global sales, 2004-05 Table 1.5: Global cancer market sales by drug class, 2004-05 Table 1.6: Gold standard treatments and limitations Table 2.7: The World Cancer Report - 5 year survival rates Table 2.8: Incidence and prevalence for 9 cancers in 2005, for 7 major markets (US, Japan, France, Germany, Italy, Spain, UK) Table 2.9: Pipeline cancer drugs by indication, 2006 Table 2.10: Data indicating unmet need in cancers based on the numbers of patients globally, 2002 Table 3.11: Cancer vaccine pipeline, 2006 Table 3.12: siRNA drug pipeline, 2006 More market research reports? Go to http://www.reportlinker.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion